Printed from https://ideas.repec.org/s/spr/pharme2.html
Content
March 2023, Volume 41, Issue 3
- 307-319 Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy
by Chen-Han Chueh & Yi-Wen Tsai & Zi-Rong Chen & Ming-Neng Shiu & Yu-Wen Wen & Nai-Jung Chiang - 321-327 Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?
by R. Brett McQueen & Kelly E. Anderson & Joseph F. Levy & Josh J. Carlson - 329-338 The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned
by Sahar Al Shabasy & Bram Roudijk & Maggie Abbassi & Aureliano Finch & Elly Stolk & Samar Farid
February 2023, Volume 41, Issue 2
- 119-121 Best Practices: A Collection of Systematic Critical Reviews of Modeling Approaches in Specific Disease Areas
by J. Jaime Caro - 123-138 How is the Societal Perspective Defined in Health Technology Assessment? Guidelines from Around the Globe
by Tuba Saygın Avşar & Xiaozhe Yang & Paula Lorgelly - 139-153 The Societal Cost of Schizophrenia: An Updated Systematic Review of Cost-of-Illness Studies
by Claire Lin & Xiaoyu Zhang & Huajie Jin - 155-174 Psychometric Properties of Generic Preference-Weighted Measures for Children and Adolescents: A Systematic Review
by Rachel Lee-Yin Tan & Sonia Zhi Yi Soh & Le Ann Chen & Michael Herdman & Nan Luo - 175-186 Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based Payment Arrangement
by Amy Gye & Stephen Goodall & Richard Abreu Lourenco - 187-198 Mapping the Patient-Reported Outcomes Measurement Information System (PROMIS-29) to EQ-5D-5L
by Mona Aghdaee & Yuanyuan Gu & Kompal Sinha & Bonny Parkinson & Rajan Sharma & Henry Cutler - 199-207 Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study
by Mónica Hernández Alava & Steve Pudney & Allan Wailoo - 209-225 Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
by Carla Rognoni & Camilla Falivena & Francesco Costa & Patrizio Armeni
January 2023, Volume 41, Issue 1
- 5-19 Health Economic Evaluation Using Markov Models in R for Microsoft Excel Users: A Tutorial
by Nathan Green & Felicity Lamrock & Nichola Naylor & Jack Williams & Andrew Briggs - 21-32 Extensions of Health Economic Evaluations in R for Microsoft Excel Users: A Tutorial for Incorporating Heterogeneity and Conducting Value of Information Analyses
by Nichola R. Naylor & Jack Williams & Nathan Green & Felicity Lamrock & Andrew Briggs - 33-42 Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Ben Wijnen & Willem Witlox & Robert Wolff & Debra Fayter & Bram Ramaekers & Thomas Otten & Steve Ryder & Pawel Posadzki & Gill Worthy & Lisa Stirk & Nigel Armstrong & Jos Kleijnen & Manuela Joore - 43-57 Patient Preferences in Targeted Pharmacotherapy for Cancers: A Systematic Review of Discrete Choice Experiments
by Shan Jiang & Ru Ren & Yuanyuan Gu & Varinder Jeet & Ping Liu & Shunping Li - 59-75 The Costs of Dementia in Europe: An Updated Review and Meta-analysis
by Linus Jönsson & Ashley Tate & Oskar Frisell & Anders Wimo - 77-91 Cost-Utility Analysis of Universal Maternal Pertussis Immunisation in Thailand: A Comparison of Two Model Structures
by Siobhan Botwright & Ei Mon Win & Nattiya Kapol & Sirikanlaya Benjawan & Yot Teerawattananon - 93-105 Health-Related Quality-of-Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis
by Corneliu Bolbocean & Sylvia Pal & Stef Buuren & Peter J. Anderson & Peter Bartmann & Nicole Baumann & Jeanie L. Y. Cheong & Brian A. Darlow & Lex W. Doyle & Kari Anne I. Evensen & John Horwood & Marit S. Indredavik & Samantha Johnson & Neil Marlow & Marina Mendonça & Yanyan Ni & Dieter Wolke & Lianne Woodward & Erik Verrips & Stavros Petrou - 107-117 Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service
by Pierluigi Russo & Matteo Zanuzzi & Angelica Carletto & Annalisa Sammarco & Federica Romano & Andrea Manca
December 2022, Volume 40, Issue 12
- 1131-1142 Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries
by Leah Z. Rand & Aaron S. Kesselheim - 1143-1158 Economic Implications of Endometriosis: A Review
by Josep Darbà & Alicia Marsà - 1159-1186 A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia
by Rumjhum Agrawal & Joao Vieira & Jacqueline Ryan & Harish Negi & Tanvi Rajput & Regina Corbin & Ricardo Viana - 1187-1205 Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting
by Xinyue Dong & Xiaoning He & Jing Wu - 1207-1220 Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial
by Edna Keeney & Sabina Sanghera & Richard M. Martin & Roman Gulati & Fredrik Wiklund & Eleanor I. Walsh & Jenny L. Donovan & Freddie Hamdy & David E. Neal & J. Athene Lane & Emma L. Turner & Howard Thom & Mark S. Clements - 1221-1234 Conceptual Framework for Optimised Proxy Value Set Selection Through Supra-National Value Set Development for the EQ-5D Instruments
by Agata Łaszewska & Ayesha Sajjad & Jan Busschbach & Judit Simon & Leona Hakkaart-van Roijen - 1235-1246 Efficiency of the EmERGE Pathway of Care in Five European HIV Centres
by Eduard J. Beck & Sundhiya Mandalia & Platon Yfantopoulos & Agathe Leon & Marie J. Merino & Felipe Garcia & Marie Wittevogel & Ludwig Apers & Ivana Benkovic & Sime Zekan & Josip Begovac & Ana S. Cunha & Eugenio Teofilo & Goncalo Rodrigues & Margarida D. F. Borges & Duncan Fatz & Jamie Vera & Jennifer Whetham - 1247-1259 Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer’s Perspective
by Tingting Qu & Shujing Zhang & Yichen Zhong & Yang Meng & He Guo & Seongjung Joo & Peter C. Enzinger - 1261-1263 Comment on “An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”
by Bhaskar Rege & James McGrory & Sabina Gasper & David McDonnell - 1265-1267 Response to Comment on “An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”
by Marjanne A. Piena & Natalie Houwing & Carla W. Kraan & Xiaofeng Wang & Heidi Waters & Craig Bennison
November 2022, Volume 40, Issue 11
- 1015-1032 A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process
by Fang Li & Frederike Jörg & Xinyu Li & Talitha Feenstra - 1033-1042 Integrating the Biology of Cardiovascular Disease into the Epidemiology of Economic Decision Modelling via Mendelian Randomisation
by Zanfina Ademi & Jedidiah I. Morton & Danny Liew & Stephen J. Nicholls & Sophia Zoungas & Brian A. Ference - 1043-1067 Are We Agreed? Self- Versus Proxy-Reporting of Paediatric Health-Related Quality of Life (HRQoL) Using Generic Preference-Based Measures: A Systematic Review and Meta-Analysis
by Diana Khanna & Jyoti Khadka & Christine Mpundu-Kaambwa & Kiri Lay & Remo Russo & Julie Ratcliffe - 1069-1079 Valuing the Quality-of-Life Aged Care Consumers (QOL-ACC) Instrument for Quality Assessment and Economic Evaluation
by Julie Ratcliffe & Siobhan Bourke & Jinhu Li & Brendan Mulhern & Claire Hutchinson & Jyoti Khadka & Rachel Milte & Emily Lancsar - 1081-1093 Is EQ-5D-5L Better Than EQ-5D-3L Over Time? A Head-to-Head Comparison of Responsiveness of Descriptive Systems and Value Sets from Nine Countries
by Mathieu F. Janssen & Ines Buchholz & Dominik Golicki & Gouke J. Bonsel - 1095-1105 A Proposal of a Cost-Effectiveness Modeling Approach for Heart Failure Treatment Assessment: Considering the Short- and Long-Term Impact of Hospitalization on Event Rates
by Gian Luca Di Tanna & Blake Angell & Michael Urbich & Peter Lindgren & Thomas A. Gaziano & Gary Globe & Björn Stollenwerk - 1107-1117 The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA
by Ali Tafazzoli & Scott D. Ramsey & Alissa Shaul & Ameya Chavan & Weicheng Ye & Anuraag R. Kansal & Josh Ofman & A. Mark Fendrick - 1119-1130 Engaging Patients and Caregivers in an Early Health Economic Evaluation: Discerning Treatment Value Based on Lived Experience
by Mackenzie Wilson & Kednapa Thavorn & Terry Hawrysh & Ian D. Graham & Harold Atkins & Natasha Kekre & Doug Coyle & Manoj M. Lalu & Dean A. Fergusson & Kelvin K. W. Chan & Daniel A. Ollendorf & Justin Presseau
October 2022, Volume 40, Issue 10
- 931-941 Tools for the Economic Evaluation of Precision Medicine: A Scoping Review of Frameworks for Valuing Heterogeneity-Informed Decisions
by Reka E. Pataky & Stirling Bryan & Mohsen Sadatsafavi & Stuart Peacock & Dean A. Regier - 943-956 Current Practices for Accounting for Preference Heterogeneity in Health-Related Discrete Choice Experiments: A Systematic Review
by Suzana Karim & Benjamin M. Craig & Caroline Vass & Catharina G. M. Groothuis-Oudshoorn - 957-969 China Health Related Outcomes Measures (CHROME): Development of a New Generic Preference-Based Measure for the Chinese Population
by Jing Wu & Xiaoning He & Pinan Chen & Shitong Xie & Xue Li & Hao Hu & Kun Zhao & Feng Xie - 971-977 Collaborating with Patient Partners to Model Clinical Care Pathways in Major Depressive Disorder: The Benefits of Mixing Evidence and Lived Experience
by Mary Bunka & Shahzad Ghanbarian & Linda Riches & Ginny Landry & Louisa Edwards & Alison M. Hoens & Stirling Bryan - 979-988 Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA
by Jing Voon Chen & James C. Gahn & Jeffrey Nesheim & Paul N. Mudd, - 989-1003 A Comparison of the Content and Consistency of Methodological Quality and Transferability Checklists for Reviewing Model-Based Economic Evaluations
by Ka Keat Lim & Rositsa Koleva-Kolarova & Julia Fox-Rushby - 1005-1009 Developing an Online Infrastructure to Enhance Model Accessibility and Validation: The Peer Models Network
by Stephanie Harvard & Amin Adibi & Adam Easterbrook & Gregory R. Werker & David Murphy & Don Grant & Alison Mclean & Zhina Majdzadeh & Mohsen Sadatsafavi - 1011-1012 Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine”
by Nikolaos Giannelos & Marie Libérée Nishimwe & Nicolas Lecrenier - 1013-1014 Authors’ Reply to Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison Between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine”
by Joke Bilcke & Philippe Beutels
September 2022, Volume 40, Issue 9
- 837-850 Carers’ Health-Related Quality of Life in Global Health Technology Assessment: Guidance, Case Studies and Recommendations
by Becky Pennington & Jack Eaton & Anthony J Hatswell & Helen Taylor - 851-861 Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Thomas Otten & Rob Riemsma & Ben Wijnen & Nigel Armstrong & Lisa Stirk & Caroline Gordon & Bram Ramaekers & Jos Kleijnen & Manuela Joore & Sabine Grimm - 863-882 A Systematic Review of the Methodologies and Modelling Approaches Used to Generate International EQ-5D-5L Value Sets
by Donna Rowen & Clara Mukuria & Emily McDool - 883-899 Best–Worst Scaling and the Prioritization of Objects in Health: A Systematic Review
by Ilene L. Hollin & Jonathan Paskett & Anne L. R. Schuster & Norah L. Crossnohere & John F. P. Bridges - 901-915 Does the Structure Matter? An External Validation and Health Economic Results Comparison of Event Simulation Approaches in Severe Obesity
by Björn Schwander & Klaus Kaier & Mickaël Hiligsmann & Silvia Evers & Mark Nuijten - 917-928 The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada
by Christopher Hillis & Colin Vicente & Graeme Ball - 929-930 Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective”
by Afschin Gandjour
August 2022, Volume 40, Issue 8
- 743-750 A Framework for Integrating Continuous Glucose Monitor-Derived Metrics into Economic Evaluations in Type 1 Diabetes
by Ágnes Benedict & Emily R. Hankosky & Kinga Marczell & Jieling Chen & David J. Klein & J. Jaime Caro & Jay P. Bae & Brian D. Benneyworth - 751-776 The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review
by Michal Witkowski & Søren Ilsøe Moreno & João Fernandes & Pierre Johansen & Margarida Augusto & Sunita Nair - 777-790 Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective
by Keith W. Pratz & Xinglei Chai & Jipan Xie & Lei Yin & Xiaoyu Nie & Melissa Montez & Erica Iantuono & Lisa Downs & Esprit Ma - 791-806 Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease
by Katya Galactionova & Paola Salari & Renato Mattli & Yael Rachamin & Rahel Meier & Matthias Schwenkglenks - 807-821 Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia
by Rachel Song & Varinder Jeet & Rajan Sharma & Martin Hoyle & Bonny Parkinson - 823-833 The Opportunity of Point-of-Care Diagnostics in General Practice: Modelling the Effects on Antimicrobial Resistance
by Simon Pol & Danielle E. M. C. Jansen & Alike W. Velden & Christopher C. Butler & Theo J. M. Verheij & Alex W. Friedrich & Maarten J. Postma & Antoinette D. I. Asselt - 835-835 Correction to: Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease
by Katya Galactionova & Paola Salari & Renato Mattli & Yael Rachamin & Rahel Meier & Matthias Schwenkglenks
July 2022, Volume 40, Issue 7
- 647-652 Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers
by Jakub P. Hlávka & Tara A. Lavelle & Peter J. Neumann & Pei-Jung Lin - 653-661 Considerations Around Coding the Membership Probability Function in a Latent Class Analysis: Renewed Insights
by Marco Boeri & Brett Hauber & Joseph C. Cappelleri - 663-698 Preference Elicitation Techniques Used in Valuing Children’s Health-Related Quality-of-Life: A Systematic Review
by Cate Bailey & Martin Howell & Rakhee Raghunandan & Amber Salisbury & Gang Chen & Joanna Coast & Jonathan C. Craig & Nancy J. Devlin & Elisabeth Huynh & Emily Lancsar & Brendan J. Mulhern & Richard Norman & Stavros Petrou & Julie Ratcliffe & Deborah J. Street & Kirsten Howard & Rosalie Viney - 699-714 Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
by Hardik Goswami & Adnan Alsumali & Yiling Jiang & Matthias Schindler & Elizabeth R. Duke & Joshua Cohen & Andrew Briggs & Amy Puenpatom - 715-724 Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China
by Yichen Zhang & Yuxuan Wei & Huangqianyu Li & Yixuan Chen & Yiran Guo & Sheng Han & Luwen Shi & Xiaodong Guan - 725-737 Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study
by Shuxia Qin & Xuehong Wang & Sini Li & Chongqing Tan & Xiaohui Zeng & Xia Luo & Lidan Yi & Liubao Peng & Meiyu Wu & Ye Peng & Liting Wang & Xiaomin Wan - 739-740 Risk-Adjusted Performance Measures: A Comment on Elbasha
by Pedram Sendi & Matthias Schwenkglenks - 741-742 Authors’ Reply to Comment on “Risk-Adjusted Performance Measures”
by Elamin H. Elbasha
June 2022, Volume 40, Issue 6
- 577-586 Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges
by Manuel Gomes & Nick Latimer & Marta Soares & Sofia Dias & Gianluca Baio & Nick Freemantle & Dalia Dawoud & Allan Wailoo & Richard Grieve - 587-599 Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability
by Zsombor Zrubka & Márta Péntek & Lea Mhanna & Teebah Abu-Zahra & Mohamed Mahdi-Abid & Meriem Fgaier & Faris El-Dahiyat & Hana Al-Abdulkarim & Michael Drummond & László Gulácsi - 601-609 Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations
by Don Husereau & Michael Drummond & Federico Augustovski & Esther Bekker-Grob & Andrew H. Briggs & Chris Carswell & Lisa Caulley & Nathorn Chaiyakunapruk & Dan Greenberg & Elizabeth Loder & Josephine Mauskopf & C. Daniel Mullins & Stavros Petrou & Raoh-Fang Pwu & Sophie Staniszewska - 611-621 A Comparison of Methods for Identifying Informal Carers: Self-Declaration Versus a Time Diary
by Sean Urwin & Yiu-Shing Lau & Gunn Grande & Matt Sutton - 623-631 Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer
by Woojung Lee & William B. Wong & Stacey Kowal & Louis P. Garrison & David L. Veenstra & Meng Li - 633-645 Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups
by Ellen Rafferty & Mike Paulden & Sarah A. Buchan & Joan L. Robinson & Julie A. Bettinger & Manoj Kumar & Lawrence W. Svenson & Shannon E. MacDonald
May 2022, Volume 40, Issue 5
- 479-488 Exploring the Issues of Valuing Child and Adolescent Health States Using a Mixed Sample of Adolescents and Adults
by Donna Rowen & Clara Mukuria & Philip A. Powell & Allan Wailoo - 489-495 Assessments of the Value of New Interventions Should Include Health Equity Impact
by Jeroen P. Jansen & Thomas A. Trikalinos & Kathryn A. Phillips - 497-507 Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches
by Elamin H. Elbasha - 509-518 Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Sabine E. Grimm & Willem Witlox & Robert Wolff & Annette Chalker & Mickael Hiligsmann & Ben Wijnen & Charlotte Ahmadu & Steve Ryder & Nigel Armstrong & Steven Duffy & Isabel Syndikus & Jos Kleijnen & Manuela A. Joore - 519-558 Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review
by Min Huang & Amin Haiderali & Grace E. Fox & Andrew Frederickson & Javier Cortes & Peter A. Fasching & Joyce O’Shaughnessy - 559-574 The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England
by K. Ray Chaudhuri & A. Simon Pickard & Ali Alobaidi & Yash J. Jalundhwala & Prasanna L. Kandukuri & Yanjun Bao & Julia Sus & Glynn Jones & Christian Ridley & Julia Oddsdottir & Seyavash Najle-Rahim & Matthew Madin-Warburton & Weiwei Xu & Anette Schrag - 575-575 Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Sabine E. Grimm & Willem Witlox & Robert Wolff & Annette Chalker & Mickael Hiligsmann & Ben Wijnen & Charlotte Ahmadu & Steve Ryder & Nigel Armstrong & Steven Duffy & Isabel Syndikus & Jos Kleijnen & Manuela A. Joore
April 2022, Volume 40, Issue 4
- 359-366 Calibrating Natural History of Cancer Models in the Presence of Data Incompatibility: Problems and Solutions
by Olena Mandrik & Chloe Thomas & Sophie Whyte & James Chilcott - 367-378 Economic Evaluation of Digital Health Interventions: Methodological Issues and Recommendations for Practice
by Manuel Gomes & Elizabeth Murray & James Raftery - 379-431 Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures
by Joseph Kwon & Louise Freijser & Elisabeth Huynh & Martin Howell & Gang Chen & Kamran Khan & Shahd Daher & Nia Roberts & Conrad Harrison & Sarah Smith & Nancy Devlin & Kirsten Howard & Emily Lancsar & Cate Bailey & Jonathan Craig & Kim Dalziel & Alison Hayes & Brendan Mulhern & Germaine Wong & Julie Ratcliffe & Stavros Petrou - 433-447 The EQ-5D-5L Valuation Study in Egypt
by Sahar Al Shabasy & Maggie Abbassi & Aureliano Finch & Bram Roudijk & Darrin Baines & Samar Farid - 449-460 Projected New-Onset Cardiovascular Disease by Socioeconomic Group in Australia
by Kaitlyn Hastings & Clara Marquina & Jedidiah Morton & Dina Abushanab & Danielle Berkovic & Stella Talic & Ella Zomer & Danny Liew & Zanfina Ademi - 461-476 Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine
by Zoë Pieters & Benson Ogunjimi & Philippe Beutels & Joke Bilcke - 477-478 Correction to: Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures
by Joseph Kwon & Louise Freijser & Elisabeth Huynh & Martin Howell & Gang Chen & Kamran Khan & Shahd Daher & Nia Roberts & Conrad Harrison & Sarah Smith & Nancy Devlin & Kirsten Howard & Emily Lancsar & Cate Bailey & Jonathan Craig & Kim Dalziel & Alison Hayes & Brendan Mulhern & Germaine Wong & Julie Ratcliffe & Stavros Petrou
March 2022, Volume 40, Issue 3
- 241-248 Four Aspects Affecting Health Economic Decision Models and Their Validation
by Talitha Feenstra & Isaac Corro-Ramos & Dominique Hamerlijnck & George Voorn & Salah Ghabri - 249-256 Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time
by Gemma E. Shields & Becky Pennington & Ash Bullement & Stuart Wright & Jamie Elvidge - 257-268 Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence Models
by Min Huang & Scott Ramsey & Weiguang Xue & Jipan Xie & James Pellissier & Andrew Briggs - 269-295 Deprescribing Interventions among Community-Dwelling Older Adults: A Systematic Review of Economic Evaluations
by Sónia Romano & Débora Figueira & Inês Teixeira & Julian Perelman - 297-307 A Comparison of PROPr and EQ-5D-5L Value Sets
by Tianxin Pan & Brendan Mulhern & Rosalie Viney & Richard Norman & Janel Hanmer & Nancy Devlin - 309-321 Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol
by Fan Yang & Kenneth R. Katumba & Bram Roudijk & Zhihao Yang & Paul Revill & Susan Griffin & Perez N. Ochanda & Mohammed Lamorde & Giulia Greco & Janet Seeley & Mark Sculpher - 323-339 Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
by Timothy Spelman & William L. Herring & Yuanhui Zhang & Michael Tempest & Isobel Pearson & Ulrich Freudensprung & Carlos Acosta & Thibaut Dort & Robert Hyde & Eva Havrdova & Dana Horakova & Maria Trojano & Giovanna Luca & Alessandra Lugaresi & Guillermo Izquierdo & Pierre Grammond & Pierre Duquette & Raed Alroughani & Eugenio Pucci & Franco Granella & Jeannette Lechner-Scott & Patrizia Sola & Diana Ferraro & Francois Grand’Maison & Murat Terzi & Csilla Rozsa & Cavit Boz & Raymond Hupperts & Vincent Pesch & Celia Oreja-Guevara & Anneke Walt & Vilija G. Jokubaitis & Tomas Kalincik & Helmut Butzkueven - 341-354 Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment
by Gabin F. Morillon & Thomas G. Poder - 355-355 Correction to: Contextual Considerations and Recommendations for Estimating the Value of Alzheimer’s Disease Therapies
by T. Joseph Mattingly & R. Brett McQueen & Pei-Jung Lin - 357-357 Correction to: Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment
by Gabin F. Morillon & Thomas G. Poder
February 2022, Volume 40, Issue 2
- 141-147 Future Offspring Costs in Economic Evaluation
by Evelyn Verbeke & Jeroen Luyten - 149-156 Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency
by Gemma E. Shields & Mark Wilberforce & Paul Clarkson & Tracey Farragher & Arpana Verma & Linda M. Davies - 157-182 How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents
by Cate Bailey & Kim Dalziel & Paula Cronin & Nancy Devlin & Rosalie Viney - 183-201 Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review
by Thitima Kongnakorn & Grammati Sarri & Andreas Freitag & Kinga Marczell & Paulina Kazmierska & Elizabeth Masters & Vivek Pawar & Xinke Zhang - 203-214 The Utility of a Rapid Review Evaluation Process to a National HTA Agency
by Áine Varley & Lesley Tilson & Emer Fogarty & Laura McCullagh & Michael Barry - 215-223 The Value of Genomic Testing: A Contingent Valuation Across Six Child- and Adult-Onset Genetic Conditions
by Yan Meng & Philip M. Clarke & Ilias Goranitis - 225-232 Is an Orphan Drug’s Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?
by James D. Chambers & Nikoletta M. Margaretos & Daniel E. Enright & Rosa Wang & Xin Ye - 233-239 The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS
by Megan Perry-Duxbury & James Lomas & Miqdad Asaria & Pieter Baal
December 2022, Volume 40, Issue 2
- 123-127 EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions
by Nancy Devlin & Bram Roudijk & Rosalie Viney & Elly Stolk - 129-137 Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L
by David J. Mott & Nancy J. Devlin & Simone Kreimeier & Richard Norman & Koonal K. Shah & Oliver Rivero-Arias - 139-146 Findings from a Roundtable Discussion with US Stakeholders on Valuation of the EQ-5D-Y-3L
by Jonathan L. Nazari & A. Simon Pickard & Ning Yan Gu - 147-155 Estimating an EQ-5D-Y-3L Value Set for China
by Zhihao Yang & Jie Jiang & Pei Wang & Xuejing Jin & Jing Wu & Yu Fang & Da Feng & Xiaoyu Xi & Shunping Li & Mingxia Jing & Bin Zheng & Weidong Huang & Nan Luo - 157-167 Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values
by Titi Sahidah Fitriana & Bram Roudijk & Fredrick Dermawan Purba & Jan J. V. Busschbach & Elly Stolk - 169-180 An EQ-5D-Y-3L Value Set for Belgium
by Sarah Dewilde & Bram Roudijk & Nafthali H. Tollenaar & Juan M. Ramos-Goñi - 181-192 In a Child’s Shoes: Composite Time Trade-Off Valuations for EQ-5D-Y-3L with Different Proxy Perspectives
by Stefan A. Lipman & Brigitte A. B. Essers & Aureliano P. Finch & Ayesha Sajjad & Peep F. M. Stalmeier & Bram Roudijk - 193-203 A Value Set for the EQ-5D-Y-3L in the Netherlands
by Bram Roudijk & Ayesha Sajjad & Brigitte Essers & Stefan Lipman & Peep Stalmeier & Aureliano Paolo Finch - 205-215 Value Set for the EQ-5D-Y-3L in Hungary
by Fanni Rencz & Gábor Ruzsa & Alex Bató & Zhihao Yang & Aureliano Paolo Finch & Valentin Brodszky - 217-229 EQ-5D-Y Value Set for Germany
by Simone Kreimeier & David Mott & Kristina Ludwig & Wolfgang Greiner - 231-231 Correction to: EQ-5D-Y Value Set for Germany
by Simone Kreimeier & David Mott & Kristina Ludwig & Wolfgang Greiner
January 2022, Volume 40, Issue 1
- 5-6 CHEERS to 30 Years of PharmacoEconomics
by Richard Milne & Christopher Carswell - 7-11 In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era
by Werner Brouwer & Samare Huls & Ayesha Sajjad & Tim Kanters & Leona Hakkaart-van Roijen & Job Exel - 13-29 The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe
by Natalie Bohm & Sarah Bermingham & Frank Grimsey Jones & Daniela C. Gonçalves-Bradley & Alex Diamantopoulos & Jessica R. Burton & Hamish Laing - 31-43 Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates
by Laura C. Edney & James Lomas & Jonathan Karnon & Laura Vallejo-Torres & Niek Stadhouders & Jonathan Siverskog & Mike Paulden & Ijeoma P. Edoka & Jessica Ochalek - 45-64 Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review
by Thomas Ward & Ruben E. Mujica-Mota & Anne E. Spencer & Antonieta Medina-Lara - 65-76 A General Public Study on Preferences and Welfare Impacts of Antimicrobial Resistance in the United Kingdom
by Maria Veronica Dorgali & Alberto Longo & Caroline Vass & Gemma Shields & Roger Harrison & Riccardo Scarpa & Marco Boeri - 77-90 Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic
by Samare P. I. Huls & Ayesha Sajjad & Tim A. Kanters & Leona Hakkaart-van Roijen & Werner B. F. Brouwer & Job Exel - 91-108 The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing–Remitting Multiple Sclerosis
by Laurenske A. Visser & Marc Folcher & Claudia Delgado Simao & Biotza Gutierrez Arechederra & Encarna Escudero & Carin A. Uyl-de Groot & William Ken Redekop - 109-120 Biased Survival Predictions When Appraising Health Technologies in Heterogeneous Populations
by Daniel Gallacher & Peter Kimani & Nigel Stallard - 121-131 An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia
by Marjanne A. Piena & Natalie Houwing & Carla W. Kraan & Xiaofeng Wang & Heidi Waters & Ruth A. Duffy & Suresh Mallikaarjun & Craig Bennison - 133-135 Preoperative Intravenous Iron for Iron Deficiency is Cost-Effective Prior to Major Elective Surgery
by Kevin M. Trentino & Hamish Mace & Axel Hofmann - 137-138 Authors’ Response to “Preoperative Intravenous Iron for Iron Deficiency is Cost-Effective Prior to Major Elective Surgery”
by Bert Avau & Hans Van Remoortel & Emmy De Buck & Veerle Compernolle & Philippe Vandekerckhove - 139-139 Correction to: A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population
by Emily McDool & Clara Mukuria & John Brazier
April 2022, Volume 40, Issue 1
- 3-5 Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, But Many Unknowns Remain
by Chris Skedgel - 7-10 Importance of Patient Involvement in the Value Assessment Process: On the Way Towards Personalised Treatments
by Nicole Gusset - 11-38 Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management
by Noman Paracha & Pollyanna Hudson & Stephen Mitchell & C. Simone Sutherland - 39-67 Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers
by C. Simone Sutherland & Pollyanna Hudson & Stephen Mitchell & Noman Paracha - 69-89 Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)
by Noman Paracha & Pollyanna Hudson & Stephen Mitchell & C. Simone Sutherland - 91-102 Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom
by Siu Hing Lo & Ksenija Gorni & C. Simone Sutherland & Yasmina Martí & Andrew Lloyd & Noman Paracha - 103-115 Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European Countries
by Siu Hing Lo & Claire Lawrence & Yasmina Martí & Andreia Café & Andrew J. Lloyd - 117-117 Correction to: Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, But Many Unknowns Remain
by Chris Skedgel - 119-119 Correction to: Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)
by Noman Paracha & Pollyanna Hudson & Stephen Mitchell & C. Simone Sutherland
December 2021, Volume 39, Issue 12
- 1355-1363 Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting
by Simon Pol & Paula Rojas Garcia & Fernando Antoñanzas Villar & Maarten J. Postma & Antoinette D. I. Asselt - 1365-1372 Why the Gap in Evaluating the Social Constructs and the Value of Medicines?
by Jacquelyn McRae & Eberechukwu Onukwugha - 1373-1381 A Practical Guide to Modeling and Conducting a Cost-Effectiveness Analysis of Companion Biomarker Tests for Targeted Therapies Using R: Tutorial Paper
by Mikyung Kelly Seo & Mark Strong - 1383-1395 Conceptualising ‘Benefits Beyond Health’ in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis
by Lidia Engel & Stirling Bryan & David G. T. Whitehurst - 1397-1410 Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Sabine E. Grimm & Ben Wijnen & Rob Riemsma & Debra Fayter & Nigel Armstrong & Charlotte Ahmadu & Lloyd Brandts & Kate Misso & John R. Kirwan & Jos Kleijnen & Manuela A. Joore - 1411-1427 Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review
by Simon van der Pol & Paula Rojas Garcia & Maarten J. Postma & Fernando Antoñanzas Villar & Antoinette D. I. Asselt - 1429-1442 Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
by Martijn J. H. G. Simons & Valesca P. Retèl & Bram L. T. Ramaekers & Rogier Butter & Joanne M. Mankor & Marthe S. Paats & Joachim G. J. V. Aerts & Zakile A. Mfumbilwa & Paul Roepman & Veerle M. H. Coupé & Carin A. Uyl-de Groot & Wim H. van Harten & Manuela A. Joore - 1443-1454 What Aspects of Illness Influence Public Preferences for Healthcare Priority Setting? A Discrete Choice Experiment in the UK
by Liz Morrell & James Buchanan & Sian Rees & Richard W. Barker & Sarah Wordsworth - 1455-1463 Assessing Technologies for COVID-19: What are the Challenges for Health Technology Assessment Agencies? Findings From a Survey and Roundtable Workshop
by Jamie Elvidge & Dalia Dawoud
November 2021, Volume 39, Issue 11
- 1201-1208 Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic
by Yumi Asukai & Andrew Briggs & Louis P. Garrison & Benjamin P. Geisler & Peter J. Neumann & Daniel A. Ollendorf - 1209-1223 The Challenges of Measuring Informal Care Time: A Review of the Literature
by Sean Urwin & Yiu-Shing Lau & Gunn Grande & Matt Sutton - 1225-1241 The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature
by Boshen Jiao & Anirban Basu & Joshua Roth & M. Bender & Ilsa Rovira & Traci Clemons & Dalyna Quach & Scott Ramsey & Beth Devine - 1243-1269 How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment
by Michael Schlander & Karla Hernandez-Villafuerte & Chih-Yuan Cheng & Jorge Mestre-Ferrandiz & Michael Baumann - 1271-1297 A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome
by I-Wen Pan & Daniel M. Halperin & Bumyang Kim & James C. Yao & Ya-Chen Tina Shih - 1299-1308 EQ-5D-Y Population Norms for Japanese Children and Adolescents
by Takeru Shiroiwa & Takashi Fukuda - 1309-1325 Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial
by Michael Dolph & Gabriel Tremblay & Hoyee Leong - 1327-1341 Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment
by Bassem Asker & Raghad Jawad & Rabah Asreah & Haydar Jamal & Ahmed Jassem & Muslim Abdelkareem Inaya & Hiwa Abou Baker & Sam Kozma & Eid Mansour & Bryony McNamara & Ryan Miller & Oliver Darlington & Phil McEwan & Daniel M. Sugrue & Haidar Jarallah - 1343-1354 Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective
by Adnan Alsumali & Laurence M Djatche & Andrew Briggs & Rongzhe Liu & Ibrahim Diakite & Dipen Patel & Yufei Wang & Dominik Lautsch
October 2021, Volume 39, Issue 10
- 1101-1107 Contextual Considerations and Recommendations for Estimating the Value of Alzheimer’s Disease Therapies
by T. Joseph Mattingly & R. Brett McQueen & Pei-Jung Lin - 1109-1121 A Review of Utility Measurement Methods Used in Pharmacoeconomic Submissions to HIRA in South Korea: Methodological Consistency and Areas for Improvement
by Jihyung Hong & Eun-Young Bae - 1123-1139 Lack of Cost-Effectiveness of Preoperative Erythropoiesis-Stimulating Agents and/or Iron Therapy in Anaemic, Elective Surgery Patients: A Systematic Review and Updated Analysis
by Bert Avau & Hans Van Remoortel & Jorien Laermans & Geertruida Bekkering & Dean Fergusson & Jørgen Georgsen & Paola Maria Manzini & Yves Ozier & Emmy De Buck & Veerle Compernolle & Philippe Vandekerckhove - 1141-1149 Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson’s Disease: A Swedish Register-Based Study in 1823 Observations
by Jenny M. Norlin & Klas Kellerborg & Per Odin - 1151-1162 Valuing SF-6Dv2 in Australia Using an International Protocol
by Brendan Mulhern & Richard Norman & John Brazier - 1163-1183 Lifetime Costs for Treated Follicular Lymphoma Patients in the US
by Caitlin Eichten & Qiufei Ma & Thomas E. Delea & May Hagiwara & Roberto Ramos & Şerban R. Iorga & Jie Zhang & Richard T. Maziarz - 1185-1196 State of the ART? Two New Tools for Risk Communication in Health Technology Assessments
by Sabine E. Grimm & Xavier Pouwels & Bram L. T. Ramaekers & Ben Wijnen & Thomas Otten & Janneke Grutters & Manuela A. Joore - 1197-1198 Deterministic Sensitivity Analysis Under Ignorance
by Afschin Gandjour - 1199-1199 Comment on “Deterministic Sensitivity Analysis Under Ignorance”
by Rick A. Vreman & Joost W Geenen & Saskia Knies & Aukje K. Mantel-Teeuwisse & Hubert G. M. Leufkens & Wim G. Goettsch
September 2021, Volume 39, Issue 9
- 973-982 Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia
by Anna Reyes-Travé & Laura Guarga-Solé & Marta Roig-Izquierdo & Enrique Alonso-Pérez & Ana Clopés-Estela & Joaquín Delgadillo-Duarte - 983-993 Aspects and Challenges of Resource Use Measurement in Health Economics: Towards a Comprehensive Measurement Framework
by Luca M. M. Janssen & Ruben M. W. A. Drost & Aggie T. G. Paulus & Kirsty Garfield & William Hollingworth & Sian Noble & Joanna C. Thorn & Irina Pokhilenko & Silvia M. A. A. Evers - 995-1019 Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review
by Joseph Khoa Ho & Kennedy Borle & Nick Dragojlovic & Manrubby Dhillon & Vanessa Kitchin & Nicola Kopac & Colin Ross & Larry D. Lynd - 1021-1044 Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel
by Karen M. Facey & Jaime Espin & Emma Kent & Angèl Link & Elena Nicod & Aisling O’Leary & Entela Xoxi & Inneke Vijver & Anna Zaremba & Tatyana Benisheva & Andrius Vagoras & Sheela Upadhyaya - 1045-1058 Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective
by Daniel Stellato & Marroon E. Thabane & Jinhee Park & David Chandiwana & Thomas E. Delea - 1059-1073 A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine
by Erin Kirwin & Ellen Rafferty & Kate Harback & Jeff Round & Christopher McCabe - 1075-1084 Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT)
by Michael J. Zoratti & Kelvin K. W. Chan & Don Husereau & Murray Krahn & Mitchell Levine & Lehana Thabane & Feng Xie - 1085-1098 Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment
by Aureliano Paolo Finch & Eva Gamper & Richard Norman & Rosalie Viney & Bernhard Holzner & Madeleine King & Georg Kemmler - 1099-1099 Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
by Becky Pennington & Abualbishr Alshreef & Laura Flight & Andrew Metry & Edith Poku & Philip Hykin & Sobha Sivaprasad & A. Toby Prevost & Joana C. Vasconcelos & Caroline Murphy & Joanna Kelly & Yit Yang & Andrew Lotery & Michael Williams & John Brazier
August 2021, Volume 39, Issue 8
- 869-878 Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals
by Tushar Srivastava & Nicholas R. Latimer & Paul Tappenden - 879-887 Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies
by Ana Duarte & Simon Walker & Andrew Metry & Ruth Wong & Jasmina Panovska-Griffiths & Mark Sculpher - 889-900 Do Costs in the Education Sector Matter? A Systematic Literature Review of the Economic Impact of Psychosocial Problems on the Education Sector
by Irina Pokhilenko & Luca M. M. Janssen & Silvia M. A. A. Evers & Ruben M. W. A. Drost & Lena Schnitzler & Aggie T. G. Paulus - 901-912 Utility Values Associated with Atypical Hemolytic Uremic Syndrome-Related Attributes: A Discrete Choice Experiment in Five Countries
by Kate Williams & Daniel Aggio & Peter Chen & Katerina Anokhina & Andrew J. Lloyd & Yan Wang - 913-927 Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
by Becky Pennington & Abualbishr Alshreef & Laura Flight & Andrew Metry & Edith Poku & Philip Hykin & Sobha Sivaprasad & A. Toby Prevost & Joana C. Vasconcelos & Caroline Murphy & Joanna Kelly & Yit Yang & Andrew Lotery & Michael Williams & John Brazier - 929-940 A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population
by Emily McDool & Clara Mukuria & John Brazier - 941-952 The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden
by Fredrik O. L. Nilsson & Sandra T. Asanin & Elizabeth T. Masters & Laura Iadeluca & Chrissy Almond & Miranda Cooper & Sarah Smith - 953-964 Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer
by Yat Hang To & Koen Degeling & Suzanne Kosmider & Rachel Wong & Margaret Lee & Catherine Dunn & Grace Gard & Azim Jalali & Vanessa Wong & Maarten IJzerman & Peter Gibbs & Jeanne Tie - 965-967 Comment on Keeney et al.’s “Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening”
by James F. O’Mahony - 969-970 Response to Comment on Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening
by Edna Keeney & Howard Thom & Emma Turner & Richard M. Martin & Sabina Sanghera - 971-971 Retraction Note to: The EQ-5D-5L Valuation Study in Egypt
by Sahar A. Shabasy & Maggie M. Abbassi & Aureliano Paolo Finch & Darrin Baines & Samar F. Farid
July 2021, Volume 39, Issue 7
- 741-756 Healthcare Funding Decisions and Real-World Benefits: Reducing Bias by Matching Untreated Patients
by Peter Ghijben & Dennis Petrie & Silva Zavarsek & Gang Chen & Emily Lancsar - 757-770 Overview and Use of Tools for Selecting Modelling Techniques in Health Economic Studies
by Huajie Jin & Stewart Robinson & Wenru Shang & Evanthia Achilla & David Aceituno & Sarah Byford - 771-788 Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine
by Heleen Vellekoop & Simone Huygens & Matthijs Versteegh & László Szilberhorn & Tamás Zelei & Balázs Nagy & Rositsa Koleva-Kolarova & Apostolos Tsiachristas & Sarah Wordsworth & Maureen Rutten-van Mölken - 789-807 Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review
by Jalal Dahham & Rana Rizk & Ingrid Kremer & Silvia M. A. A. Evers & Mickaël Hiligsmann - 809-822 What are the Economic Costs to Society Attributable to Alcohol Use? A Systematic Review and Modelling Study
by Jakob Manthey & Syed Ahmed Hassan & Sinclair Carr & Carolin Kilian & Sören Kuitunen-Paul & Jürgen Rehm - 823-833 Health Economists on Involving Patients in Modeling: Potential Benefits, Harms, and Variables of Interest
by Stephanie Harvard & Gregory R. Werker - 835-851 Cost-of-Illness Progression Before and After Diagnosis of Multiple Sclerosis: A Nationwide Register-Based Cohort Study in Sweden of People Newly Diagnosed with Multiple Sclerosis and a Population-Based Matched Reference Group
by Chantelle Murley & Petter Tinghög & Kristina Alexanderson & Jan Hillert & Emilie Friberg & Korinna Karampampa - 853-867 Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2− Advanced Breast Cancer: A Canadian Healthcare Perspective
by Daniel Stellato & Marroon E. Thabane & David Chandiwana & Jinhee Park & Thomas E. Delea
June 2021, Volume 39, Issue 6
- 617-617 Introduction to the Special Issue of PharmacoEconomics on Major Depressive Disorders
by Paul E. Greenberg & Tammy Sisitsky - 619-625 The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers
by David Proudman & Paul Greenberg & Dave Nellesen - 627-630 Overlap of Depressive Symptoms with Health-Related Quality-of-Life Measures
by Ron D. Hays & Peter M. Fayers - 631-638 Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States
by Richard Z. Xie & Erica deFur Malik & Mark T. Linthicum & Jennifer L. Bright